All In Biotech

Drug Trial Radar · NCT05890781

Engineering Immune Organoids to Study Pediatric Cancer

Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

May 12, 2023

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Conditions

  • Brain Tumor
  • Kidney Tumor
  • Neuroblastoma
  • Sarcoma

Interventions

  • Skin biopsyProcedure

    Skin biopsy

  • Fresh tumor sampleProcedure

    Fresh tumor sample

  • Blood sampleBiological

    Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

  • Healthy tissue from the tumorProcedure

    Healthy tissue from the tumor site whenever possible

  • Spinal cerebrospinal fluid (SCF)Procedure

    Spinal cerebrospinal fluid (SCF) whenever possible

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of viable and exploitable immune organoids with engrafted tumor cellsTime frame: until 5 years after enrolment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Hopital Necker

    Paris, Île-de-France Region, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.